NMT1 and NMT2 Localization Markers for ER+ Breast Cancer Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current endocrine therapies for ER+ breast cancer face issues with de novo and developed resistance, and there is a need for improved methods to predict prognosis and treatment response in breast cancer patients.
Innovation Solution
Determine the nuclear and cytoplasmic levels of NMT1 and the cellular localization of NMT2 in breast cancer cells to predict prognosis and develop NMT2 serine phosphorylation inhibitors to prevent nuclear localization, thereby improving treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional endocrine therapies (tamoxifen, aromatase inhibitors) are used to treat breast cancer, then treatment response is achieved in some patients, but de novo and acquired resistance develops
Solution Approach 1:
The patent introduces NMT1 and NMT2 as intermediary proteins that mediate the resistance mechanism between endocrine therapy and breast cancer cells. These proteins act as molecular bridges that explain why therapies fail over time, providing a target for overcoming resistance without changing the existing therapy paradigm
Solution Approach 2:
The patent changes the diagnostic parameter from traditional biomarkers to cellular localization patterns of NMT proteins. By analyzing whether NMT1/NMT2 are cytoplasmic or nuclear, the system provides a new parameter for predicting treatment response and resistance, enabling personalized therapy selection
2Measurement precision
If traditional prognostic markers are used for breast cancer, then basic risk assessment is provided, but prediction precision for treatment response is insufficient
Solution Approach 1:
The patent segments the NMT protein into two distinct isoforms (NMT1 and NMT2) with different localization patterns. This segmentation allows independent analysis of each protein's role in treatment response, providing more precise prognostic information than treating them as a single entity
Solution Approach 2:
The patent adds a new dimension to prognostic assessment by incorporating subcellular localization data (cytoplasmic vs. nuclear positioning) alongside traditional expression levels. This dimensional expansion enables differentiation between patients who will respond to endocrine therapy versus those who will develop resistance
Data Source
AI summary
High levels of nuclear NMT1 are associated with longer relapse free survival in ERα positive breast cancer patients. Both low levels of cytosolic and nuclear NMT1 correlated to very poor clinical outcomes. NMT2 also plays an important function in breast cancer signalling, regulated through phosphorylation. For example, NMT2 phosphorylation status is a key element in the progression of ER+ breast cancer cells. Specifically, nuclear localization of NMT2 is associated with poor outcomes in breast cancer patients.